Acquisitions:
1. Aurobindo Pharma USA has signed a definitive agreement to acquire 100% of Lannett Company Inc., from Lannett Seller Holdco for US$ 250 million.
2. Alembic Pharmaceuticals has acquired Utility Therapeutics for US$ 12 million to strengthen its presence in the U.S. market.
3. Zydus Lifesciences has completed the acquisition of an 85.6% stake in Amplitude Surgical, a France-based company specializing in lower limb orthopedics.
4. Corona Remedies has acquired seven brands from Bayer in India, expanding its domestic product portfolio.
5. Sanofi has announced plans to acquire early-stage vaccine developer Vicebio for US$ 1.15 billion upfront, reinforcing its vaccine pipeline.
6. ArchiMed will acquire dental device manufacturer ZimVie in a US$ 730 million transaction.
7. Otsuka Pharmaceutical has entered into a partnership and licensing deal with Cantargia valued at up to US$ 613 million, marking a strategic move into cancer immunotherapy.
Licensing:
1. Glenmark’s subsidiary IGI has out-licensed its cancer trispecific antibody program to AbbVie in a deal valued at up to US$1.9 billion.
2. Lupin has signed a license and supply agreement with Zentiva to commercialize Certolizumab in select European markets.
3. Emcure Pharmaceuticals will market Sanofi’s oral diabetes brands in India under a strategic marketing agreement.
4. Alexion, the rare disease arm of AstraZeneca, has signed an US$825 million licensing agreement with Japan’s JCR Pharmaceuticals for access to AAV capsids to support its genomic medicine pipeline.
5. Debiopharm has licensed a first-in-class cancer drug from Repare Therapeutics, with an upfront payment of US$10 million and additional milestone-based payments.
Investment:
1. Cipla has announced an investment in iCaltech, aimed at strengthening its presence in the respiratory therapy segment.
2. Sai Parenterals has successfully completed a US$ 5.82 million (?50 crore) equity funding round, backed by a group of marquee investors to support its expansion plans.
3. Varda Space Industries has raised US$ 187 million to advance its space-based drug manufacturing platform, marking a major step in next-gen biomanufacturing.
4. NFL Biosciences has secured US$ 1.31 million (€1.2 million) in non-dilutive funding, supplementing its recent capital raise to support the development of NFL-101, a first-in-class therapy for tobacco addiction.
Co-development:
1. AbbVie has entered into a US$ 700 million collaboration agreement with Glenmark’s U.S. subsidiary Ichnos Sciences to develop and commercialize a novel trispecific antibody for cancer treatment.
2. Boehringer Ingelheim has partnered with LEO Pharma to co-develop and commercialize Spevigo, a treatment targeting inflammatory skin conditions.
3. Neuraxpharm and Dizlin Pharmaceuticals have announced a global co-development agreement to advance a next-generation drug-device therapy for patients with advanced Parkinson’s disease.
Aagami Updates:
1. Success for Client: In the last ~45 days Aagami has secured 12 investments for its California based client with Novel and portable MRI (with AI and robotic-guidance) system for in-office use.
2. US client developing revolutionary treatment for Infectious diseases granted a contract extension to Aagami.
3. Aagami Research Team (ART) has prepared a report , highlighting select cross border deals of Indian companies covering Jan 2023 – Mar 2025.
a. The deals reveal robust activity across acquisitions, investments, licensing, and strategic collaborations, highlighting India’s expanding global footprint.
b. If you would like to receive a complimentary copy of the report, please contact us.
4. Aagami CEO Dinesh Jain, completed a successful business Trip to India.
5. Aagami to participate in the following partnering conferences:
a. ASIA BIO Partnering Forum | SEP 09-10, 2025 | Singapore (Partnering Opens August 12th)
b. Bio Japan | OCT 08-10, 2025 | Yokohama, Japan
c. BIO-EUROPE | NOV 03-05, 2025 | Vienna, Austria
Select opportunities available with us:
For Partnering/Licensing/ Co-development:
1. Seeking Co-development Partner/Investor/EPO supplier for Phase 3 stage Erythropoietin (EPO) patented asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach). By using the 351(A) dossier, an easy and quick path via 351 (K) Biosimilar approval for multiple indications may also be obtained.
2. Seeking Co-development/Out-Licensing: Phase 3 stage small molecule first-in-class eye drop to treat pre-surgical cataract (typically for patients under 72 years of age).
4. Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses (RSV, FLU, COVID). Also, Phase 2 trials are starting in Central Africa for MPOX. Very effective in Bird Flu and Measles too.
For Acquisition:
1. A High Multiple ROI by acquiring clinical asset in rare diseases (sickle cell disease & thalassemia). (Two Phase 1 completed. Phase 2 ready).
2. Lucrative Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic.
3. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics.
4. Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).
For Investment:
1. High ROI Opportunity to Invest in U.S.based medtech revolutionizing medical imaging with the world’s first portable, single-sided MRI platform (On the market). With over US $70 Million raised in current round, our client is offering special terms to invest in current B-4/B-5 round. Expected ROI is 2-4x in 12-18 months via an IPO, strategic M&A, or private equity buyout.
Hope you found the content useful. We welcome your feedback and queries.